These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 24634380)

  • 21. CD70 antibody-drug conjugate as a potential therapeutic agent for uterine leiomyosarcoma.
    Nakae R; Matsuzaki S; Serada S; Matsuo K; Shiomi M; Sato K; Nagase Y; Matsuzaki S; Nakagawa S; Hiramatsu K; Okazawa A; Kimura T; Egawa-Takata T; Kobayashi E; Ueda Y; Yoshino K; Naka T; Kimura T
    Am J Obstet Gynecol; 2021 Feb; 224(2):197.e1-197.e23. PubMed ID: 32822640
    [TBL] [Abstract][Full Text] [Related]  

  • 22. AKT1-CREB stimulation of PDGFRα expression is pivotal for PTEN deficient tumor development.
    Wan X; Zhou M; Huang F; Zhao N; Chen X; Wu Y; Zhu W; Ni Z; Jin F; Wang Y; Hu Z; Chen X; Ren M; Zhang H; Zha X
    Cell Death Dis; 2021 Feb; 12(2):172. PubMed ID: 33568640
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma.
    Lee JW; Stone RL; Lee SJ; Nam EJ; Roh JW; Nick AM; Han HD; Shahzad MM; Kim HS; Mangala LS; Jennings NB; Mao S; Gooya J; Jackson D; Coleman RL; Sood AK
    Clin Cancer Res; 2010 May; 16(9):2562-70. PubMed ID: 20388851
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of Endothelial SCUBE2 (Signal Peptide-CUB-EGF Domain-Containing Protein 2), a Novel VEGFR2 (Vascular Endothelial Growth Factor Receptor 2) Coreceptor, Suppresses Tumor Angiogenesis.
    Lin YC; Liu CY; Kannagi R; Yang RB
    Arterioscler Thromb Vasc Biol; 2018 May; 38(5):1202-1215. PubMed ID: 29545238
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Investigating a chimeric anti-mouse PDGFRα antibody as a radiosensitizer in primary mouse sarcomas.
    Song EJ; Ashcraft KA; Lowery CD; Mowery YM; Luo L; Ma Y; Campos LDS; Cardona DM; Stancato L; Kirsch DG
    EBioMedicine; 2019 Feb; 40():224-230. PubMed ID: 30711517
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer.
    Bianco R; Caputo R; Caputo R; Damiano V; De Placido S; Ficorella C; Agrawal S; Bianco AR; Ciardiello F; Tortora G
    Clin Cancer Res; 2004 Jul; 10(14):4858-64. PubMed ID: 15269162
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Platelet derived growth factor receptor alpha mediates nodal metastases in papillary thyroid cancer by driving the epithelial-mesenchymal transition.
    Ekpe-Adewuyi E; Lopez-Campistrous A; Tang X; Brindley DN; McMullen TP
    Oncotarget; 2016 Dec; 7(50):83684-83700. PubMed ID: 27845909
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of evodiamine on PI3K/Akt and MAPK/ERK signaling pathways in pancreatic cancer cells.
    Hong Z; Wang Z; Zhou B; Wang J; Tong H; Liao Y; Zheng P; Jamshed MB; Zhang Q; Chen H
    Int J Oncol; 2020 Mar; 56(3):783-793. PubMed ID: 31922213
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The N-terminal polypeptide derived from viral macrophage inflammatory protein II reverses breast cancer epithelial-to-mesenchymal transition via a PDGFRα-dependent mechanism.
    Yang QL; Zhang LY; Wang HF; Li Y; Wang YY; Chen TT; Dai MF; Wu HH; Chen SL; Wang WR; Wu Q; Chen CJ; Zhou CZ
    Oncotarget; 2017 Jun; 8(23):37448-37463. PubMed ID: 28415580
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy.
    García-García C; Ibrahim YH; Serra V; Calvo MT; Guzmán M; Grueso J; Aura C; Pérez J; Jessen K; Liu Y; Rommel C; Tabernero J; Baselga J; Scaltriti M
    Clin Cancer Res; 2012 May; 18(9):2603-12. PubMed ID: 22407832
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors.
    Damiano V; Caputo R; Bianco R; D'Armiento FP; Leonardi A; De Placido S; Bianco AR; Agrawal S; Ciardiello F; Tortora G
    Clin Cancer Res; 2006 Jan; 12(2):577-83. PubMed ID: 16428503
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SHP-2-upregulated ZEB1 is important for PDGFRα-driven glioma epithelial-mesenchymal transition and invasion in mice and humans.
    Zhang L; Zhang W; Li Y; Alvarez A; Li Z; Wang Y; Song L; Lv D; Nakano I; Hu B; Cheng SY; Feng H
    Oncogene; 2016 Oct; 35(43):5641-5652. PubMed ID: 27041571
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Platelet-derived growth factor receptor alpha (PDGFRα) is overexpressed in NK/T-cell lymphoma and mediates cell survival.
    Lu L; Fu X; Li Z; Qiu Y; Li W; Zhou Z; Xue W; Wang Y; Jin M; Zhang M
    Biochem Biophys Res Commun; 2018 Oct; 504(2):525-531. PubMed ID: 30201265
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The conformational control inhibitor of tyrosine kinases DCC-2036 is effective for imatinib-resistant cells expressing T674I FIP1L1-PDGFRα.
    Shen Y; Shi X; Pan J
    PLoS One; 2013; 8(8):e73059. PubMed ID: 24009732
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells.
    Pal HC; Baxter RD; Hunt KM; Agarwal J; Elmets CA; Athar M; Afaq F
    Oncotarget; 2015 Sep; 6(29):28296-311. PubMed ID: 26299806
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The PDGFRα-laminin B1-keratin 19 cascade drives tumor progression at the invasive front of human hepatocellular carcinoma.
    Govaere O; Petz M; Wouters J; Vandewynckel YP; Scott EJ; Topal B; Nevens F; Verslype C; Anstee QM; Van Vlierberghe H; Mikulits W; Roskams T
    Oncogene; 2017 Nov; 36(47):6605-6616. PubMed ID: 28783171
    [TBL] [Abstract][Full Text] [Related]  

  • 37. GZD856, a novel potent PDGFRα/β inhibitor, suppresses the growth and migration of lung cancer cells in vitro and in vivo.
    Zhang Z; Ren X; Lu X; Wang D; Hu X; Zheng Y; Song L; Pang H; Yu R; Ding K
    Cancer Lett; 2016 May; 375(1):172-178. PubMed ID: 26940138
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-tumor activity of oridonin on SNU-5 subcutaneous xenograft model via regulation of c-Met pathway.
    Liu H; Qian C; Shen Z
    Tumour Biol; 2014 Sep; 35(9):9139-46. PubMed ID: 24916572
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antitumor effect of XCT790, an ERRα inverse agonist, on ERα-negative endometrial cancer cells.
    Kokabu T; Mori T; Matsushima H; Yoriki K; Kataoka H; Tarumi Y; Kitawaki J
    Cell Oncol (Dordr); 2019 Apr; 42(2):223-235. PubMed ID: 30706380
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Novel Pharmacodynamic Biomarker and Mechanistic Modeling Facilitate the Development of Tovetumab, a Monoclonal Antibody Directed Against Platelet-Derived Growth Factor Receptor Alpha, for Cancer Therapy.
    Liang M; Wang B; Schneider A; Vainshtein I; Roskos L
    AAPS J; 2020 Nov; 23(1):4. PubMed ID: 33210183
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.